Topic summary

Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry

Compounds › Retatrutide retatrutide randomised trial effect size preprint Solved

This is a generated summary. It shows the 5 most-liked posts from a topic of 15, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

IRenaudinTL2Member11 Jul 2026#2

Hepatic effects: glucagon receptor agonism promotes hepatic fat oxidation, which is mechanistically plausible for benefit in metabolic liver disease. Whether that translates to improved clinical outcomes is being tested in phase 2 work.

29 likes 16d

t.vargaTL2 Moderator Solution13 Jul 2026#3

Glucagon receptor agonism seems paradoxical in a weight-loss compound because glucagon raises blood glucose. The paradox resolves because glucagon agonism also increases energy expenditure and promotes hepatic fat oxidation, and the incretin components offset the glycaemic effect. In diabetes trials, HbA1c improved rather than worsened.

9 likes 15d

NardoneTL2Member17 Jul 2026#6

IRenaudin, post #2: Hepatic effects: glucagon receptor agonism promotes hepatic fat oxidation, which is mechanistically plausible for benefit in metabolic liver disease. Whether that translates to improved clinical outcomes is being tested in phase 2 work. Go to post

post #5 answers the question as asked. The question underneath it is different.

Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide (dual) to retatrutide (triple) would answer that question. The published data does not include such a direct comparison.

21 likes in reply to #2 11d

h.friskTL2 Moderator21 Jul 2026 · edited#9

t.varga, post #3: Glucagon receptor agonism seems paradoxical in a weight-loss compound because glucagon raises blood glucose. The paradox resolves because glucagon agonism also increases energy expenditure and promotes hepatic fat oxidation, and the incretin components offset the glycaemic effect. In diabetes trials, HbA1c improved rather than worsened. Go to post

Why this subcategory is more cautious than elsewhere: retatrutide is investigational, phase 3 is ongoing, and the heart-rate signal in phase 2 is not negligible. Caution is proportionate to the evidence status.

30 likes in reply to #3 7d

a.kowalczykTL2Regular23 Jul 2026#11

post #10 answers the question as asked. The question underneath it is different.

Phase 2 sample sizes are not adequate for safety characterisation of a novel triple agonist. Phase 3 is where that question gets answered. Using phase 2 results to make claims about safety profile is using the trial for a purpose it was not designed for.

26 likes 5d

Read the full topic (15 posts)

This topic was referenced in

Second pass at: Retatrutide dose escalation in the published trialsCompounds › Retatrutide · 125 replies

Promoted into the documentation commons. The content of this topic is maintained at Retatrutide — reference, with named maintainers and a review date. The promotion was discussed in doc review. Corrections are best raised against the document, which is the version that gets kept current.

Suggested topics

Topic	Participants	Replies	Views	Activity
Retatrutide's phase 2 heart-rate signal and how to think about it Compounds › Retatrutide randomised trial preprint TRIUMPH programme retatrutide On the subject in the title: Retatrutide's phase 2 heart-rate signal and how to think about it Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim…	+19	23	20k	7mo
Second pass at: Triple agonism: additive, synergistic, or neither? Compounds › Retatrutide TRIUMPH programme effect size retatrutide randomised trial Solved Under review Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen STEP 8 ( JAMA , 2022) cited in support…	+114	120	1.4k	10mo
Retatrutide phase 2 in type 2 diabetes: the Lancet paper Compounds › Retatrutide randomised trial preprint effect size retatrutide Solved Closed On the subject in the title: Retatrutide phase 2 in type 2 diabetes: the Lancet paper Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of a claim I do not think it…	+12	16	50k	12mo
The retatrutide phase 2 obesity paper, read closely Compounds › Retatrutide preprint effect size TRIUMPH programme Posting this under the heading it deserves: The retatrutide phase 2 obesity paper, read closely Everything below is what sits behind that. Session topic: STEP 8 ( JAMA , 2022). Please read it before posting;…		2	65k	10mo
Why retatrutide discussion here is more cautious than elsewhere Compounds › Retatrutide randomised trial effect size retatrutide preprint Solved Why retatrutide discussion here is more cautious than elsewhere I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited…	+7	12	7.7k	2mo

Related topics — sharing the tags retatrutide, randomised trial, effect size

Topic	Participants	Replies	Views	Activity
Second pass at: Retatrutide mass and identity: what a report should show Compounds › Retatrutide retatrutide randomised trial effect size Solved Second pass at: Retatrutide mass and identity: what a report should show — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 4 ( JAMA , 2021)…	+65	71	4.6k	13mo
When a network meta-analysis is defensible and when it is not Evidence › Meta-analyses effect size heterogeneity publication bias Solved When a network meta-analysis is defensible and when it is not I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing SUSTAIN 6 ( N Engl J Med , 2016) with LEADER (…		2	27k	4h
Journal club: LEADER as the historical anchor Evidence › Journal club estimand number needed to treat journal club effect size Pinned Journal club: LEADER as the historical anchor Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med , 2021) with SURMOUNT-4 ( JAMA , 2024) and…	+103	110	8.1k	2h
Biased agonism: a real phenomenon, an over-used explanation Pharmacology › Receptor biology semaglutide retatrutide long read tirzepatide Posting this under the heading it deserves: Biased agonism: a real phenomenon, an over-used explanation Everything below is what sits behind that. A documentation question rather than an analytical one. I…	+130	135	23k	16mo
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version Pharmacology › Receptor biology retatrutide amylin analogues semaglutide Posting this under the heading it deserves: Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version Everything below is what sits behind that. I would like to understand…	+57	63	1k	6mo